Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
2.120
-0.040 (-1.85%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Protalix BioTherapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | -6.6 | 2.93 | 8.31 | -14.93 | -27.58 | Upgrade
|
| Depreciation & Amortization | 1.47 | 1.3 | 1.19 | 1.09 | 1.12 | Upgrade
|
| Other Amortization | - | - | 0.27 | 0.3 | 2.67 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | -0 | 0.01 | - | -0.05 | Upgrade
|
| Stock-Based Compensation | 2.3 | 3.25 | 3.45 | 2.09 | 2.38 | Upgrade
|
| Other Operating Activities | 0.95 | 0.38 | -4.01 | -1.53 | 1.28 | Upgrade
|
| Change in Accounts Receivable | -5.89 | 2.32 | -0.43 | -1.19 | -1.03 | Upgrade
|
| Change in Inventory | -4.49 | -2.2 | -2.24 | 1.15 | -4.87 | Upgrade
|
| Change in Accounts Payable | 0.29 | 0.7 | 5.3 | -4.8 | 2.39 | Upgrade
|
| Change in Unearned Revenue | - | - | -13.18 | -7.16 | 13.23 | Upgrade
|
| Change in Other Net Operating Assets | -0.02 | -0 | 0.01 | -0.01 | 0.19 | Upgrade
|
| Operating Cash Flow | -11.99 | 8.67 | -1.32 | -25 | -10.29 | Upgrade
|
| Capital Expenditures | -1.64 | -1.28 | -1.15 | -0.63 | -1.46 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 0 | - | - | 0.05 | Upgrade
|
| Investment in Securities | - | 5.42 | -15.42 | -5 | 20 | Upgrade
|
| Other Investing Activities | -0.73 | 0.08 | -0.14 | 0.59 | 0.33 | Upgrade
|
| Investing Cash Flow | -2.37 | 4.22 | -16.71 | -5.04 | 18.92 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | -4.09 | Upgrade
|
| Long-Term Debt Repaid | - | -20.42 | - | - | -30.04 | Upgrade
|
| Total Debt Repaid | - | -20.42 | - | - | -34.12 | Upgrade
|
| Net Debt Issued (Repaid) | - | -20.42 | - | - | -34.12 | Upgrade
|
| Issuance of Common Stock | 9.33 | 3.63 | 24.67 | 8.24 | 46.2 | Upgrade
|
| Financing Cash Flow | 9.33 | -16.79 | 24.67 | 8.24 | 12.08 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.05 | 0.03 | -0.11 | -0.08 | 0.01 | Upgrade
|
| Net Cash Flow | -5.08 | -3.87 | 6.52 | -21.87 | 20.72 | Upgrade
|
| Free Cash Flow | -13.63 | 7.39 | -2.47 | -25.63 | -11.74 | Upgrade
|
| Free Cash Flow Margin | -25.84% | 13.84% | -3.77% | -53.80% | -30.62% | Upgrade
|
| Free Cash Flow Per Share | -0.17 | 0.09 | -0.03 | -0.53 | -0.27 | Upgrade
|
| Cash Interest Paid | - | 1.53 | 2.74 | 2.2 | 3.41 | Upgrade
|
| Cash Income Tax Paid | 1.18 | 0.39 | - | - | - | Upgrade
|
| Levered Free Cash Flow | -12.2 | 5.43 | -1.81 | -7.55 | -12.86 | Upgrade
|
| Unlevered Free Cash Flow | -11.45 | 6.1 | -0.09 | -6.27 | -10.83 | Upgrade
|
| Change in Working Capital | -10.1 | 0.81 | -10.54 | -12.02 | 9.9 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.